Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Luvox CR and Luvox
Synonyms :
Class :
Selective serotonin reuptake inhibitors and Antidepressants
Dosage Forms & Strengths Â
Tablets Â
25mg Â
50mg Â
100mg Â
Obsessive-Compulsive DisorderÂ
50 mg/day orally at bedtime or 100 mg/day orally at bedtime as needed 
or 100-300 mg/day orally
The maximum dose a day is 300 mg
(off-label):
50 mg/day orally at bedtime or 100 mg/day orally at bedtime as needed 
or 100-300 mg/day orally
The maximum dose a day is 300 mg
(off-label):
50 mg/day orally at bedtime or 100 mg/day orally at bedtime as needed 
or 100-300 mg/day orally 
The maximum dose a day is 300 mg
Posttraumatic Stress DisorderÂ
(off-label):
50 mg/day orally at bedtime or 100 mg/day orally at bedtime as needed  or 100-300 mg/day orally
The maximum dose a day is 300 mg 
Dosage Forms & Strengths Â
Tablets Â
25mg Â
50mg Â
100mg Â
Obsessive-Compulsive DisorderÂ
Age: 8-11 years: 
25 mg/day orally once at bedtime increase up to 25-200 mg/day 
The maximum dose for a day is 200 mg 
Age: 11-17 years: 
25 mg/day orally once at bedtime increase up to 25-300 mg/day 
The maximum dose for a day is 300 mg 
may have an increased antiplatelet effect when combined with NSAIDs
may increase the tachycardic effect of Alpha-/Beta-Agonists
may have an increased risk of gastrointestinal bleeding when combined with fluvoxamine
it may increase the effect of serotonergic agents
May increase the hypoglycemic effect of each other when combined
meningococcal A C Y and W-135 diphtheria conjugate vaccine
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
may diminish the metabolism of each other when combined
serotonin levels can be increased or raised when fluvoxamine is used combinely with lidocaine
it decreases the metabolism of alosetron
may increase the serotonergic effect of Rasagiline
may increase the serotonergic effect of Monoamine Oxidase Inhibitors
it may increase the antiplatelet effect of other antiplatelets agents
it may increase the antiplatelet effect of other antiplatelets agents
it may increase the antiplatelet effect of other antiplatelets agents
it may increase the antiplatelet effect of other antiplatelets agents
it may increase the antiplatelet effect of other antiplatelets agents
it may increase the effect of serotonergic agents
it may increase the effect of serotonergic agents
it may increase the effect of serotonergic agents
it may increase the effect of anticoagulants
it may increase the effect of anticoagulants
it may increase the effect of anticoagulants
it may increase the effect of anticoagulants
it may increase the effect of anticoagulants
it may increase the risk of adverse effects of antipsychotic agents
it may increase the risk of adverse effects of antipsychotic agents
it may increase the risk of adverse effects of antipsychotic agents
it may increase the risk of adverse effects of antipsychotic agents
it may increase the risk of adverse effects of antipsychotic agents
it may increase the risk of adverse effects of antipsychotic agents
it may increase the risk of adverse effects of antipsychotic agents
it may increase the risk of adverse effects of antipsychotic agents
it may increase the risk of adverse effects of antipsychotic agents
it may increase the risk of adverse effects of antipsychotic agents
it may increase the risk of adverse effects of antipsychotic agents
it may increase the risk of adverse effects of antipsychotic agents
it may increase the risk of adverse effects of antipsychotic agents
it may increase the risk of adverse effects of antipsychotic agents
it may increase the effect of serotonergic agents
it may increase the effect of serotonergic agents
it may increase the effect of serotonergic agents
it may increase the effect of serotonergic agents
it may increase the effect of serotonergic agents
it may increase the effect of serotonergic agents
it may increase the effect of serotonergic agents
it may increase the effect of serotonergic agents
it may increase the effect of serotonergic agents
it may increase the effect of serotonergic agents
it may increase the effect of other selective serotonin reuptake inhibitors
it may increase the effect of other selective serotonin reuptake inhibitors
it may increase the effect of other selective serotonin reuptake inhibitors
it may increase the effect of other selective serotonin reuptake inhibitors
it may increase the effect of other selective serotonin reuptake inhibitors
it increases the concentration of active metabolites of roflumilast-containing products in the serum
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may enhance the hypoglycemic effect
may increase the antiplatelet effect
may increase the antiplatelet effect
may increase the antiplatelet effect
may increase the antiplatelet effect
may increase the antiplatelet effect
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
When dexrabeprazole and fluvoxamine is used together, this leads to reduction in the dexrabeprazole’s metabolism
When fluvoxamine is used together with somatotropin, this leads to a rise in fluvoxamine metabolism
When encainide is used together with fluvoxamine, this leads to a reduction in the encainide’s metabolism
fluvoxamine leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
when both drugs are combined, both increase the QTC interval  
it decreases the efficacy of antianxiety agents
may increase the hypoglycemic effect of blood glucose-lowering agents
may increase the serotonergic effect of Serotonin 5-HT1D Receptor Agonists
may enhance the effect of SSRI's
may enhance the effect of SSRI's
may enhance the effect of SSRI's
may enhance the effect of SSRI's
may enhance the effect of SSRI's
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may enhance the risk of adverse effects
may increase the hypoglycemic effect of Agents with Blood Glucose Lowering Effects
It may enhance the risk of adverse effects when combined with calcium
the risk of bleeding may be increased
ascorbigen, when used in combination with fluvoxamine, the efficacy of fluvoxamine is lowered
When fluvoxamine is aided by hesperetin, it reduces hesperetin’s metabolism
Adverse drug reactions:  Â
Frequency Defined Â
>10% Â
Anorexia Â
Abnormal ejaculation Â
Nausea Â
Headache  Â
Dizziness  Â
Xerostomia  Â
Weakness Â
Insomnia Â
Somnolence Â
Diarrhea Â
1-10% Â
Abdominal pain Â
Myalgia Â
Abnormal thinking Â
Chest pain Â
Palpitation  Â
Agitation  Â
Vasodilation Â
Hypertension  Â
Abnormal taste  Â
Bruising  Â
Abnormal dreams Â
 Â
Pregnancy warnings:    Â
AU TGA Pregnancy Category: C
US FDA Pregnancy Category: CÂ
Breastfeeding warnings: Â
crosses into breast milk- knownÂ
Pregnancy Categories:      Â
 Â
Patient Information Leaflet   Â
Generic Name: fluvoxamineÂ
Why do we use fluvoxamine?Â
fluvoxamine belongs to the class of Selective serotonin reuptake inhibitors which helps to treat obsessive-compulsive disorder, Social Phobia, Panic Disorder, and Post-traumatic stress disorderÂ